Abstract
The second-generation highly immunogenic, safe and effective vaccines are available for prevention and post-exposure prophylaxis of viral hepatitis B(HBV). Gradually leads to refine knowledge of vaccination schedule variability, duration of protection, application method, the definition of high-risk people and introduction of adult vaccination.Hopeful the new third-generation vaccines produced in mammalian cell lines with new antigens, which would enhance the vaccine nonresponders and specific groups of people with minimal immune responses to existing vaccines.Development of subunit recombinant vaccines against viral hepatitis C and E is ongoing.Increasing of vaccination rate against hepatitis B in adult vaccination schedule should complete childrens routine vaccination.Combination of active hepatitis B prophylaxis, antiviral treatment and interruption of transmission of HBV could lead to elimination, eventually to eradication the disease in the population.